Covance and Quintiles will work in close partnership with Takeda to plan and execute global development programs which will support new compounds in all therapeutic areas, except oncology.
Takeda will have access to the central laboratory services and clinical development capabilities of Covance and Quintiles, both of whom will provide dedicated resources to support Takeda’s development pipeline.
The relationships will help Takeda move toward a fully virtual, global, program-level outsourcing model which will help improve its productivity and operational efficiency.
Takeda Pharmaceutical Development Division senior vice president of Global Development Operations Robert Ahlbrandt said the partnerships will improve the agility and productivity of the company’s drug development activities, and help deliver innovative new medicines.